search
Back to results

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
VX-702
Sponsored by
Vertex Pharmaceuticals Incorporated
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients 18 to 75 years of age with active RA
  • Must have been taking MTX for at least 6 months
  • No concurrent DMARD treatment (other than a stable dose of MTX)

Exclusion Criteria:

  • Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
  • Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1

Sites / Locations

  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call for Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information
  • Call For Information

Outcomes

Primary Outcome Measures

To evaluate the effects of VX-702 administered with concomitant methotrexate (MTX), and MTX alone

Secondary Outcome Measures

To evaluate the safety and tolerability of VX-702 administered with concomitant MTX, and MTX alone

Full Information

First Posted
November 1, 2006
Last Updated
December 5, 2007
Sponsor
Vertex Pharmaceuticals Incorporated
search

1. Study Identification

Unique Protocol Identification Number
NCT00395577
Brief Title
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Official Title
A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate
Study Type
Interventional

2. Study Status

Record Verification Date
December 2007
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Vertex Pharmaceuticals Incorporated

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
120 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
VX-702
Primary Outcome Measure Information:
Title
To evaluate the effects of VX-702 administered with concomitant methotrexate (MTX), and MTX alone
Secondary Outcome Measure Information:
Title
To evaluate the safety and tolerability of VX-702 administered with concomitant MTX, and MTX alone

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients 18 to 75 years of age with active RA Must have been taking MTX for at least 6 months No concurrent DMARD treatment (other than a stable dose of MTX) Exclusion Criteria: Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Kauffman, MD, PhD
Organizational Affiliation
Vertex Pharmaceuticals Incorporated
Official's Role
Study Director
Facility Information:
Facility Name
Call For Information
City
Dimitrovgrad
Country
Bulgaria
Facility Name
Call For Information
City
Pleven
Country
Bulgaria
Facility Name
Call For Information
City
Sofia
Country
Bulgaria
Facility Name
Call For Information
City
Veliko Tarnovo
Country
Bulgaria
Facility Name
Call For Information
City
Osijek
Country
Croatia
Facility Name
Call For Information
City
Zagreb
Country
Croatia
Facility Name
Call For Information
City
Belgrade
Country
Former Serbia and Montenegro
Facility Name
Call For Information
City
Niska Banja
Country
Former Serbia and Montenegro
Facility Name
Call For Information
City
Zemun
Country
Former Serbia and Montenegro
Facility Name
Call For Information
City
Bytom
Country
Poland
Facility Name
Call For Information
City
Krakow
Country
Poland
Facility Name
Call for Information
City
Torun
Country
Poland
Facility Name
Call For Information
City
Zyrardow
Country
Poland
Facility Name
Call For Information
City
Novosibirsk
Country
Russian Federation
Facility Name
Call For Information
City
Saratov
Country
Russian Federation
Facility Name
Call For Information
City
St. Petersburg
Country
Russian Federation
Facility Name
Call For Information
City
Ljubljana
Country
Slovenia

12. IPD Sharing Statement

Citations:
PubMed Identifier
19404957
Citation
Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. doi: 10.1002/art.24485. Erratum In: Arthritis Rheum. 2009 Oct;60(10):3071.
Results Reference
derived

Learn more about this trial

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

We'll reach out to this number within 24 hrs